Are cinnamon derivatives effective and safe for diabetes?
Methiye Mancak1, Ufuk Koca Çalişkan1,2
1Department of Pharmacognosy, Faculty of Pharmacy, Gazi University, Ankara, Turkiye.
Turkish Journal of Medical Sciences
|March 19, 2025
Summary
Cinnamon exhibits antidiabetic properties by inhibiting key enzymes. However, some commercial cinnamon products contain high coumarin levels, posing potential health risks and necessitating careful sourcing for therapeutic use.
Area of Science:
- Phytochemistry
- Pharmacology
- Food Science
Background:
- Cinnamon (genus *Cinnamomum*) is derived from tree bark and widely recognized for its traditional use in managing diabetes.
- The genus *Cinnamomum* encompasses around 250 species, with *C. verum*, *C. cassia*, *C. burmannii*, and *C. loureiroi* being commercially prevalent.
- Previous research highlights the antidiabetic potential of cinnamon and its byproducts.
Purpose of the Study:
- To evaluate the chemical composition of various commercial cinnamon samples.
- To assess the in vitro antidiabetic activities of these cinnamon samples.
- To determine the safety of commercially available cinnamon for health-related applications.
Main Methods:
- Macroscopic and chromatographic analyses were conducted on seven distinct cinnamon samples (sticks, tea bags, capsules).
- Enzyme inhibition assays were performed targeting diabetes-related enzymes: α-amylase, α-glucosidase, and aldose reductase.
- Quantification of key compounds, trans-cinnamaldehyde and coumarin, using high-performance liquid chromatography (HPLC).
Main Results:
- Cinnamon extracts demonstrated significant inhibition of diabetes-related enzymes.
- Trans-cinnamaldehyde levels ranged from 7.73-333.69 mg/g, and coumarin levels reached up to 43.73 mg/g in aqueous and ethanolic extracts.
- High coumarin concentrations were detected in *C. cassia*, *C. burmannii*, and *C. loureiroi* extracts, potentially indicating a health risk as per European Food Safety Authority guidelines.
- Despite observed antidiabetic activity, trans-cinnamaldehyde and coumarin were not detected in ready-made herbalist products via HPLC.
Conclusions:
- The botanical source of cinnamon is critical for its safe application in both culinary and therapeutic contexts.
- This study underscores the necessity for rigorous quality control and inspection of cinnamon products available from herbal sources.
- Variability in chemical content necessitates careful selection of cinnamon for health benefits and safety assurance.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
148
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
148
01:06Oral Hypoglycemic Agents: Glinides
120
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
120
01:23Dipeptidyl Peptidase 4 Inhibitors
148
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
148
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
139
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
139
01:17Oral Hypoglycemic Agents: Sulfonylureas
172
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
172
01:15Diabetes: Management and Pharmacotherapy
216
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
216